The present protocol describes a cuff technique for a mouse left lung transplantation model. This technique has been developed over several years and has performed well, serving effectively in immunological research.
Over the past decade, our laboratory has made significant progress in developing and refining vascularized mouse lung transplantation models using an efficient and highly reliable "cuff technique" of transplantation. This article describes a sophisticated and comprehensive method for orthotopic lung transplantation in a vascularized orthotopic lung model, representing the most physiologic and clinically relevant model of mouse lung transplantation to date. The transplantation process consists of two distinct stages: donor harvest and subsequent implantation into the recipient. The method has been successfully mastered, and with several months of sufficient training, a skilled practitioner can perform the procedure in approximately 90 min from skin-to-skin. Surprisingly, once individuals overcome the initial learning curve, the survival rate during the perioperative period approaches nearly 100%. The mouse model allows for the use of multiple commercially available transgenic and mutant strains of mice, enabling the study of tolerance and rejection. Additionally, the unique features of this model make it a valuable tool for investigating tumor biology and immunology.
While replacement therapies, such as dialysis and ventricular assist devices, exist for those with renal and heart failure, lung transplantation remains the primary treatment option for patients suffering from end-stage pulmonary disease. This procedure serves as the sole life-saving choice for individuals diagnosed with pulmonary fibrosis1. Additionally, it is employed to extend the lifespan of those facing end-stage obstructive lung diseases like emphysema, as well as those with suppurative conditions such as cystic fibrosis1.
While short-term survival rates have improved due to technical refinements, perioperative care enhancements, and advances in immunosuppression, long-term outcomes after lung transplantation are markedly inferior to those of other solid organs. The overall five-year survival rate of only 50% for lung graft recipients is much lower than for those receiving heart, kidney, or liver allografts1. Our team and others have suspected that the reason for such a discrepancy is the lack of clinically relevant biological models to fully understand pathways leading to lung allograft rejection and/or tolerance, as experimental manipulation of physiologically relevant mouse models has significantly contributed to the long-term survival of other solid or cellular allografts2.
Prior to the development of the mouse orthotopic lung transplant model, researchers relied on larger animal models for their studies. However, these larger models had limitations, including a lack of transgenic mutants required for exploring mechanistic questions3. Additionally, rat studies faced similar limitations4, and non-vascularized heterotopic tracheal transplant models in mice were also limited to their utility5. Research has shown the importance of using vascularized transplant models instead of nonvascularized ones in various organ systems. For example, nonvascularized grafts of neonatal cardiac tissue inserted into the ear pinna of recipient mice lack direct interaction with vascular endothelium and recipient bloodstream. Therefore, they are limited in their relevance compared to vascularized human cardiac grafts6. In a similar manner, the heterotopic tracheal transplant model, which lacks vascularization and aeration, differs significantly from human lung transplants, particularly in the observed airway changes in small airways after transplantation. Moreover, the rapid onset of fibrotic occlusion in heterotopic tracheal allografts does not mirror observations in human lungs or in vascularized lung grafts in larger animals or rats7.
In our research lab, the creation of the orthotopic mouse lung transplant model was inspired by the orthotopic single lung transplant model established in rats8,9. Unlike humans, mice, and rats possess only one lobe in their left lung, constituting a mere twenty-five percent of the total lung mass. This feature enables the successful execution of left lung transplantation in murine models without requiring circulatory support10,11. Over time, we have introduced technical modifications to the model, and in this context, the key steps that enhance the ease of performing the procedure are elucidated.
Beyond its implications in transplant immunobiology research, the orthotopic mouse lung transplant model offers a robust instrument for exploring the role of pulmonary non-hematopoietic stromal cells in various disease processes. This occurs because a mutant syngeneic single lung transplant leads to an almost complete replacement of hematopoietic cells with recipient-derived ones, whereas non-hematopoietic stromal cells continue to originate from the donor. Consequently, a "chimeric organ" can be created without host irradiation or lung-specific expression of a transgene12. Moreover, the opposite-side native lung can function as an internal control within the same animal without causing widespread changes to the host's immune system. This model holds great promise for advancing research in lung transplantation and other disease pathways involving pulmonary stromal cells.
All animal-related procedures were conducted in accordance with and received approval from the Institutional Animal Care and Use Committee at The University of Maryland, Baltimore. It is recommended to use male, 8-12 weeks (20-25 g), BALB/c mice as the donor and C57BL/6 mice as the recipient. The animals were obtained from a commercial source (see Table of Materials).
1. Preparation of bronchial and vascular cuffs
Timing: 10 min (for three cuffs)
2. Donor procedure
Timing: 10-15 min
3. Recipient procedure
Timing: 50-60 min
4. Animal recovery
Timing: 12 h
Based on the experience with this model over the last 10 years, individuals with basic microsurgical skills typically require a learning curve of approximately 50 animals. Once proficiency is achieved, the donor procedures typically take 15-30 minutes, while the recipient procedures take approximately 60 min. After the initial learning curve, perioperative mortality tends to be very low.
In Figure 4A,B, the lung morphology seven days following the engraftment of Balb/cJ donor left lungs into C57/B6J recipients shows that mice treated with co-stimulatory blockade exhibited preserved, normal morphology. In contrast, non-immunosuppressed mice displayed signs of rejection.
In Figure 4C,D, the H & E staining of co-stimulatory blockade-treated mice revealed minimal immunoreactivity, suggesting immune tolerance. In contrast, non-immunosuppressed mice exhibited prominent lymphocytic infiltration, indicative of a rejection response.
Figure 1: Cuff creation. Employing blade #11, (A) vascular and bronchial cuffs are made with an extension cuff handle to ease the placement. (B) 18 G/20 G/24 G catheters were used for bronchos/pulmonary vein/pulmonary artery (from left to right). Please click here to view a larger version of this figure.
Figure 2: Donor operation. The donor procedure proceeds with heparin injection through the penis vein (A), intubation (B), dissection of the diaphragm (C) and a midline sternotomy (D). The excised lung block (E) was kept moist with guaze pads covered (F). The hilum is dissected starting with the donor plumonary artery (G), pulmonary vein (H). The vessel was grabbed through the lumen of the cuff and then folded over the cuff exposing the endothelial/epithelial surface(I). Next, it was fastened with 10-0 nylon suture around the cuff (2 knots) (J). Please click here to view a larger version of this figure.
Figure 3: Recipient operation. The recipient procedure proceeds with endotracheal intubation, right lateral decubitus position (A) and a left thoracotomy (B). The recipient left lung is released from the attachments in the hilum, anterior view (C) and the recipient pulmonary artery (D), pulmonary vein (E) and bronchus are dissected. Proximal control of the recipient hilum is obtained with an aneurysm clip (F). The cuffed donor pulmonary artery is inserted into the recipient pulmonary artery through a V-shaped 1/3 arteriotomy (G) and the cuff handle is controlled by a second aneurysm clip to keep cuff stable, then secured with a 10-0 nylon tie (2 knots) (H). The 2nd clip was removed and the same procedure was followed for the pulmonary vein (I) and bronchus (J). The 1st clip was removed to let the lung reperfuse (K). the lung is inflated and then placed back in the chest (L). Please click here to view a larger version of this figure.
Figure 4: Morphology and histology of the transplanted lung. Seven days following engraftment of Balb/cJ donor left lungs into C57/B6J recipients, mice treated with co-stimulatory blockade exhibited a preserved, normal morphology (A). In contrast, non-immunosuppression treated mice displayed signs of rejection (B). H & E staining of the co-stimulatory blockade-treated mice revealed minimal immunoreactivity, suggesting immune tolerance (C). Non-immunosuppression treated mice exhibited prominent lymphocytic infiltration, indicative of a rejection response (D). Scale bars: 100 µm. Please click here to view a larger version of this figure.
The cuff technique for murine left lung transplantation represents a significant advancement in transplantation research10,11. Critical steps include precise and meticulous hilar structure dissection and secure anastomoses. Modifications can be made to suit experimental needs, but a learning curve is involved. Our group has modified the recipient mouse position from posterior to anterior, gaining a better hilum view by bending the recipient mouse, which shortens the learning curve.
Limitations include challenges with mice outside the specified weight range and the need for skilled surgeons with prior experience in microsurgery. To mitigate the risk of graft atelectasis, it is strongly advised to implement positive end-expiratory pressure (PEEP) after engraftment and ensuring the appropriate administration of analgesics. For the prevention of venous tears, it is recommended employing a smaller cuff size (22 G). Additionally, to avert arterial torsion, it is suggested to minimize the graft movement after preparation and taking utmost care when adjusting the orientation of the donor's lung during the anastomosis procedure.
Despite limitations, the method's vascularized approach surpasses nonvascularized models and provides better physiological relevance. It also overcomes shortcomings of heterotopic tracheal models7, making it an ideal model for the study of transplant immunobiology and disease processes. The model's transformative feature allows the gradual replacement of donor hematopoietic cells by host cells, facilitating research on disease and malignancy12. Additionally, it offers insights into pulmonary stromal cell contributions, essential for understanding lung pathophysiology and targeted therapies.
Overall, the cuff technique holds promise for advancing research in transplantation biology, lung diseases, and immunology, with potential applications in diverse fields. Researchers should be mindful of its learning curve and adaptability to specific research needs. We aim to improve the efficiency and success of the procedure by making practical modifications, such as repositioning the animal after thoracotomy for a better surgical view. While the core technique remains the same, these enhancements can significantly ease the process, especially for timely lung anastomosis in experimental settings. This article provides valuable tips for better technique performance in the field.
The authors have nothing to disclose relevant to the subject of this manuscript.
ASK, AEG and DK are supported by P01 AI116501. ASK and EJ are further supported by R01AI145108-01, R01HL166402. ASK is supported by I01 BX002299-05. AEG and DK are further supported by RO1HL09601. CL is supported by R01 HL128492. This work is partially supported by Chuck and Mary Meyers and Richard and Eibhlin Henggeler.
Name | Company | Catalog Number | Comments |
10-0 Nylon suture | Surgical Specialties Corporation, Reading PA | AK-0106 | |
2 Dumont #5 forceps | Fine Science Tools Inc., Foster City, CA | 11251-20 | |
2 Halsted-Mosquito clamp curved tip | Fine Science Tools Inc., Foster City, CA | 91309-12 | |
6-0 braided silk suture | Henry Schein Inc., Melville, NY, | 100-5597 | |
6-0 Polydioxanone PDS II suture and | Ethicon Inc., Somerville, NJ. | Z117H | |
70% Ethanol | Pharmco Products Inc., Brookfield, CT | 111000140 | |
Adson forceps | Fine Science Tools Inc., Foster City, CA | 91127-12 | |
Balb/c mice | Jackson Laboratories, Bar Harbor, Maine, USA | 000651 | 8–12 weeks; Male |
Bipolar coagulator | Valleylab Inc., Boulder, CO | SurgII-20, E6008/E6008B | |
C57BL/6 mice | Jackson Laboratories, Bar Harbor, Maine, USA | 000664 | 8–12 weeks; Male |
Clear chlorhexidine | Hibiclens, Mölnlycke Health Care US, LLC, Norcross, GA | 57591 | |
Electrocautery | Bovie | ||
Fine vannas style spring scissors | Fine Science Tools Inc., Foster City, CA | 15000-03 | |
Halsey needle holder | Fine Science Tools Inc., Foster City, CA | 91201-13 | |
Harvard Apparatus Mouse Ventilator VentElite | Harvard Apparatus, Holliston, MA | 55-7040 | settings 3L O2/minute, respiratory rate 130 bpm, 0.4 cc tidal volume |
Heparin solution | Abraxis Pharmaceutical Products, Schaumburg, IL | 504031 | 100 U/mL |
Injection grade normal saline | Hospira Inc., Lake Forest, IL | NDC 0409-4888-20 | |
Ketamine | VetOne, Boise, ID | 501072 | 50 mg/kg |
Konig Mixter Micro Pediatric Forceps Right-Angled Jaws | Medline, Northfield, IL, | MDS1247714 | Extra Fine, Overall Length 5 1/2" (14cm) |
Medline High Temperature Cautery,W/ Fine Tip | Leica Microsystems, Inc., Allendale, NJ | 10 450 290 | |
Microscope Leica M80 F12 Floor Stand | Fine Science Tools Inc., Foster City, CA | 15396-00 | |
Moria extra fine spring scissors | Parkland Scientific, Coral Springs, FL | V3000i | |
Ohio Isoflurane Vaporizer | Vitrolife Inc., Englewood, CO, | 19001 | |
Perfadex low-potassium dextran glucose solution | Becton Dickinson Labware, Franklin Lakes, NJ | 353025 | Electrolyte preservation solution |
polystyrene petridishes | Fine Science Tools Inc., Foster City, CA | 00632-11 and 00649-11 | 150 × 25 mm and 60 × 25 mm |
S&T SuperGrip Forceps straight and angled tip | Fine Science Tools Inc., Foster City, CA | 18200-20 | |
Small animal retraction system | Puritan Medical Company LLC, Guilford, Maine | 823-WC | tapered mini cotton tipped 3 inch applicators |
sterile Q-tips | Terumo Medical Corporation, Elkton, MD | SROX2419Z | |
Surflo etfe IV Catheter, Yellow, 24 G x 0.75" | Terumo Medical Corporation, Elkton, MD | SROX1851Z | |
Surflo etfe IV Catheter; Green, 18 G x 2" | Terumo Medical Corporation, Elkton, MD | SROX2032Z | |
Surflo etfe IV Catheter; Pink, 20 G x 1.25" | Thermocare, Inc., Incline Village, NV | ||
ThermoCare Small Animal ICU System, | A to Z Vet Supply, Dresden, TN | 008679 | 10 mg/kg |
Xylazine | Aesculap, Inc., Center Valley, PA, | FT480T | |
Yasargil Clip Applier | Aesculap, Inc., Center Valley, PA, | FT264T | |
Yasargil Temporary Aneurysm Clips | Medline, Northfield, IL, | ESCT001 |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved